WebAbstract. Immunotherapy using T cells genetically engineered to express a chimeric antigen receptor (CAR) is rapidly emerging as a promising new treatment for haematological and non-haematological malignancies. CAR-T-cell therapy can induce rapid and durable clinical responses, but is associated with unique acute toxicities, which can be severe ... Web11 de abr. de 2024 · Oh, D.-Y., & Bang, Y.-J. (2024). HER2-targeted therapies — a role beyond breast cancer. Nature Reviews Clinical Oncology. doi:10.1038/s41571-019-0268-3
Nature Reviews Clinical Oncology - Impact Factor & Score 2024 ...
WebIn this Review, we discuss the biology of NTRK fusions, strategies to target these drivers in the treatment-naive and acquired-resistance disease settings, and the unique safety profile of TRK inhibitors. Publication types Research … Web17 de ago. de 2024 · 哪些 肿瘤学( oncology ) sci 期刊容易 发表? 影响 因子是衡量期刊水平的重要指标, 一般 而言,影响因子较高的期刊投稿命中率较低,相对较难中,而影响因子 较低 的期刊则相对容易 发表 ,为方便大家投稿时选刊,耐特译根据影响因子 高低 对各个学科 期刊进行 了排名, 供大家 投稿时参考。 crj 3232
NTRK fusion-positive cancers and TRK inhibitor therapy
WebNature Reviews Clinical Oncology is one of eight Clinical Review journals published by the Nature Publishing Group. It covers research developments and clinical practice in oncology. The Chief Editor is Dr Diana Romero who works with an international Advisory Board of clinicians. ISSN 1759-4774 詳しくは ISSN (Online) 1759-4782 詳しくは 出版社 Web11 de abr. de 2024 · 《Journal of Thoracic Oncology》 所属分类: 首页 > SCI期刊 > 医学 期刊名: Journal of Thoracic Oncology 期刊名缩写: J THORAC ONCOL 期刊ISSN: 1556-0864 E-ISSN: 1556-1380 2024年影响因子/JCR分区: 20.121/Q1 学科与分区: ONCOLOGY - SCIE (Q1); RESPIRATORY SYSTEM - SCIE (Q1) 出版国家或地区: … Webدنیای سلامت و دارو (@donyayesalamatvadarou) on Instagram: ". علل افزایش نرخ سرطان در بزرگسالان زیر ۵۰ سال ... crj 3305